KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xylem (XYL) EBT (2016 - 2025)

Xylem (XYL) has 16 years of EBT data on record, last reported at $368.0 million in Q4 2025.

  • For Q4 2025, EBT fell 1.87% year-over-year to $368.0 million; the TTM value through Dec 2025 reached $1.2 billion, up 8.65%, while the annual FY2025 figure was $1.2 billion, 8.65% up from the prior year.
  • EBT reached $368.0 million in Q4 2025 per XYL's latest filing, up from $297.0 million in the prior quarter.
  • Across five years, EBT topped out at $375.0 million in Q4 2024 and bottomed at $17.0 million in Q3 2022.
  • Average EBT over 5 years is $192.7 million, with a median of $187.0 million recorded in 2022.
  • Peak YoY movement for EBT: plummeted 87.22% in 2022, then surged 988.24% in 2023.
  • A 5-year view of EBT shows it stood at $126.0 million in 2021, then surged by 50.0% to $189.0 million in 2022, then grew by 11.11% to $210.0 million in 2023, then skyrocketed by 78.57% to $375.0 million in 2024, then fell by 1.87% to $368.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $368.0 million in Q4 2025, $297.0 million in Q3 2025, and $299.0 million in Q2 2025.